{"analyses":[{"ciLowerLimit":"0.71","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.02","estimateComment":"Nivolumab over Sorafenib; Stratified Cox proportional hazard model","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","otherAnalysisDescription":"95.81% CI ADJUSTED FOR MULTIPLICITY: (0.72 to 1.02)","pValue":"0.0752","pValueComment":"A priori threshold for statistical significance is 0.0419","paramType":"Hazard Ratio (HR)","paramValue":"0.85","statisticalComment":"Log-rank Test stratified by the stratification factors as entered into the IVRS","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.93","upperLimit":"18.37","value":"16.39"},{"groupId":"OG001","lowerLimit":"11.89","upperLimit":"17.22","value":"14.69"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"371"},{"groupId":"OG001","value":"372"}],"units":"Participants"}],"description":"OS is defined as the time from the date of randomization to the date of death due to any cause in all randomized participants. Participants who are alive will be censored at the last known alive dates.\n\nBased on Kaplan-Meier Estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 240 mg intravenously (IV) every 2 weeks until disease progression or unacceptable toxicity","id":"OG000","title":"Nivolumab 240 mg"},{"description":"Sorafenib 400 mg orally (PO) twice a day (BID) until disease progression or unacceptable toxicity","id":"OG001","title":"Sorafenib 400 mg"}],"paramType":"MEDIAN","populationDescription":"all randomized participants","reportingStatus":"POSTED","timeFrame":"time from the date of randomization to the date of death due to any cause, assessed up to June 2019 (approximately 41 months)","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}